• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Uncertainties Cloud Evidence for Closed-Loop Vasopressor Systems in Critical Care

by
November 18, 2026
in Health
Reading Time: 4 mins read
0
Uncertainties Cloud Evidence for Closed-Loop Vasopressor Systems in Critical Care

Uncertainties Cloud Evidence for Closed-Loop Vasopressor Systems in Critical Care

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A systematic review and meta-analysis of closed-loop vasopressor (CLV) systems confirms improved short-term target adherence in hemodynamic management, yet a critique by Mistry and Nair in the Journal of Clinical Monitoring and Computing suggests the findings warrant cautious interpretation. The original review by Alvarado-Sánchez et al., which serves as a meta-analysis of this emerging technological field, provided a useful synthesis of automated hemodynamic control. However, the critique highlights significant methodological inconsistencies regarding patient classification, eligibility criteria, and statistical reporting that impact the generalisability of the reported results.

The review characterized its scope as including five perioperative trials and one intensive care unit (ICU) study. However, Mistry and Nair note that the COMAT trial, which enrolled patients with severe brain injury in a nonoperative neurocritical care setting, contributed data to all three forest plots assessing hemodynamic control. Furthermore, two other trials focused on postoperative ICU care following complex surgery. The critics argue that grouping nonoperative neurocritical care patients with perioperative surgical patients complicates the assessment of the clinical populations where CLV systems are intended for use. They suggest that separating intraoperative, postoperative ICU, and nonoperative ICU evidence would more accurately describe the populations represented and the limits of generalisability.

The critique also questions the consistency of the study eligibility criteria. The reviewers’ prespecified methodology required that trials report at least one hemodynamic-control outcome: the percentage of time within a target band, or time spent in hypotensive or hypertensive states. Despite this, a trial by Merouani et al. was included in the quantitative analysis of total norepinephrine dose, even though it did not report any of the required hemodynamic-control outcomes. Mistry and Nair note this creates confusion regarding how secondary outcomes influenced study inclusion. They advocate for greater transparency in distinguishing which studies met the primary criteria, as this lack of clarity affects the overall strength of the evidence.

Variations in how studies defined hemodynamic-control outcomes create further complications. The review pooled results for ‘percentage time within target,’ but definitions varied significantly across trials: two intraoperative trials used a 20-mm Hg band, two postoperative ICU trials used a 10-mm Hg band, and the COMAT trial used a 10-mm Hg band around a clinician-selected target. Because the percentage of time within a target is intrinsically sensitive to the chosen bandwidth and the placement of that band, the critics observe that the pooled mean difference of 33.94 percentage points may partly reflect these structural differences in outcome construction rather than a transportable effect of the CLV therapy itself. They suggest that future sensitivity analyses should account for these diverse target definitions.

Concerns regarding the statistical interpretation of adverse events also emerge from the critique. The review’s protocol specified a fixed-effects model when I² heterogeneity was below 50 percent, and a random-effects model when I² was 50 percent or higher. However, Mistry and Nair observe that Figure 4 reported random-effects estimates for both major and minor adverse events despite I² values of 30 percent and 10 percent, respectively. Furthermore, safety outcomes were markedly imprecise. Major adverse events were based on data from only three trials, resulting in an RR of 0.73 with a 95 percent confidence interval of 0.15 to 3.44 and a prediction interval of 0.00 to 1606.87. For minor events, the RR was 1.08 with a 95 percent confidence interval of 0.46 to 2.53 and a prediction interval of 0.04 to 28.23. Because these intervals span both potential benefit and harm, the critics question the moderate and high certainty assigned to these outcomes, as GRADE typically suggests downgrading evidence when confidence intervals include clinically important effects in both directions.

The critique also addresses the study’s search methodology. The authors searched MEDLINE, Embase, Scopus, Web of Science, the Cochrane Library, and the Cochrane Central Register of Controlled Trials (CENTRAL). Mistry and Nair note that the Cochrane Library is a collection of multiple databases, and CENTRAL is a database specifically focused on trials that is already housed within the Cochrane Library. They describe searching both simultaneously as methodologically redundant. While this does not fundamentally invalidate the study’s conclusions, the critique emphasizes that strict adherence to standardized systematic review protocols is necessary for robust evidence synthesis.

Concluding their assessment, Mistry and Nair maintain that these points do not invalidate the original review’s central observation that closed-loop vasopressor systems show promise in improving short-term target adherence. However, the range of valid inferences that can be drawn from the pooled estimates is narrower than previously suggested. They emphasize that correcting study classification, clarifying eligibility decisions, implementing sensitivity analyses that account for non-equivalent target definitions, and reevaluating the certainty assigned to safety outcomes are necessary steps to strengthen the interpretation of future research. This exchange underscores the necessity for transparent methodology as these automated technologies move toward broader clinical implementation in high-acuity environments.

Subject of Research: Methodological critique of meta-analysis on closed-loop vasopressor systems

Article Title: Closed-loop vasopressor systems: surrogate benefit, heterogeneous targets, and uncertain generalisability

Article References: Mistry, T., & Nair, A. S. (2026). Closed-loop vasopressor systems: surrogate benefit, heterogeneous targets, and uncertain generalisability. Journal of Clinical Monitoring and Computing. https://doi.org/10.1007/s10877-026-01512-1

Image Credits: AI Generated

DOI: 10.1007/s10877-026-01512-1

Keywords: Closed-loop vasopressor systems, Hemodynamic control, Meta-analysis, Systematic review, Critical care medicine, Perioperative care, Clinical monitoring, Evidence-based medicine, Statistical heterogeneity, Norepinephrine, Patient safety, Hemodynamic targets, Medical technology, Study classification, Research methodology, Outcome measurement, Neurocritical care, Vasopressors

News Source: Ophelia Keating. (November 18, 2026). Uncertainties Cloud Evidence for Closed-Loop Vasopressor Systems in Critical Care. Scienmag.

Tags: clinical monitoringClosed-loop vasopressor systemscritical care medicineEvidence-based medicineHemodynamic controlHemodynamic targetsmedical technologyMeta-analysisneurocritical carenorepinephrineoutcome measurementPatient Safetyperioperative careresearch methodologystatistical heterogeneityStudy classificationsystematic reviewvasopressors
Share12Tweet7Share2ShareShareShare1

Related Posts

Entacapone Remains Chemically Stable in Feeding Tube Suspensions With Magnesium Oxide

Entacapone Remains Chemically Stable in Feeding Tube Suspensions With Magnesium Oxide

November 18, 2026
Southeastern Groundskeepers Face Elevated Hand-Arm Vibration and Severe Heat Stress

Southeastern Groundskeepers Face Elevated Hand-Arm Vibration and Severe Heat Stress

November 18, 2026

Young Adults Using Stimulants Report High Unmet Harm Reduction Needs in Seattle

November 18, 2026

Adding Lateral Procedures to ACL Reconstruction May Aid Graft Maturation Without Clinical Gains

November 18, 2026

POPULAR NEWS

  • Electroacupuncture Mobilizes Unique CD34-Positive Stem-Like Cells in Healthy Dogs

    Electroacupuncture Mobilizes Unique CD34-Positive Stem-Like Cells in Healthy Dogs

    29 shares
    Share 12 Tweet 7
  • Specialists Outline Cervical Cancer Screening Principles for Resource-Limited Settings

    29 shares
    Share 12 Tweet 7
  • Modified Halpern Proximal Algorithm Solves Multi-Structured Problems in Curved Hadamard Spaces

    29 shares
    Share 12 Tweet 7
  • Machine Learning Outperforms Pharmacokinetic Models Predicting Initial Vancomycin Concentrations in Septic Patients

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Entacapone Remains Chemically Stable in Feeding Tube Suspensions With Magnesium Oxide

Southeastern Groundskeepers Face Elevated Hand-Arm Vibration and Severe Heat Stress

Young Adults Using Stimulants Report High Unmet Harm Reduction Needs in Seattle

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.